Skip to search formSkip to main contentSkip to account menu

pan FGFR Inhibitor PRN1371

Known as: FGFR 1-4 Inhibitor PRN1371, PRN 1371, PRN1371 
A highly specific covalent inhibitor of human fibroblast growth factor receptor types 1, 2, 3 and 4 (FGFR1-4) with potential antiangiogenic and… 
National Institutes of Health

Related topics

Related topics

1 relation
Receptor Tyrosine Kinase Inhibition

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Abstract B22: Exposure of AZD4547 FGFR-TKI to a lung squamous carcinoma cell line induces resistance by small cell lung cancer-like transformation associated with ASCL1
Molecular targeted medicine has progressed in non-small cell lung cancer in recent years, and acquired resistance to molecular… 
2017
2017
Abstract 2091: PRN1371, an irreversible, covalent inhibitor of FGFR1-4 exhibits sustained pathway inhibition in cancer cell lines
Introduction: Multiple human cancers harbor alterations in FGFRs that drive tumor growth, including mutations, translocations and… 
2016
2016
A phase 1, multicenter, dose-escalation study of PRN1371, an irreversible covalent FGFR1-4 kinase inhibitor, in patients with advanced solid tumors, followed by expansion cohorts in patients with…
TPS2602Background: FGFR inhibition is a promising therapeutic approach in a number of solid tumors where genetic alterations of… 
2016
2016
Abstract 4996: Targeting FGFR4 with monoclonal antibodies as therapeutic agents for the treatment of rhabdomyosarcoma
Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA Rhabdomyosarcoma (RMS) is the most common soft… 
2016
2016
Abstract SY30-01: Discovery of the highly selective covalent FGFR1-4 inhibitor PRN1371, currently in development for the treatment of solid tumors
Discovering drug candidates that exhibit durable on-target pharmacology upon oral dosing has been extremely challenging for the… 
2016
2016
Abstract 1249: PRN1371, an irreversible, covalent inhibitor of FGFR1, 2, 3 and 4 is highly efficacious in preclinical tumor models
Introduction: Multiple human cancers harbor alterations in FGFRs that drive tumor growth, including mutations, translocations and… 
2016
2016
Polythérapie fgfr/pd-1 destinée au traitement du cancer
La presente invention concerne des polytherapies destinees au traitement du cancer. En particulier, les procedes de l'invention… 
2012
2012
FGFR-Fc 융합단백질 및 용도
본 발명은 생물기술영역에 속하며 질병의 치료에 관련되고 더욱이 FGF의 과도발현과 상관되는 질병의 치료에 연관된다. 구체적으로 본 발명은 FGFR-Fc 융합단백질 및 FGFR-Fc… 
2012
2012
A Computational Model of Fibroblast Growth Factor-2 Binding to Endothelial Cells Under Fluid Flow
Fibroblast growth factor-2 (FGF2) is an angiogenic growth factor that binds to cell surface receptors (FGFR) and heparan sulfate… 
2001
2001
Mechanisms Growth by Both Angiogenesis-dependent and-independent Factor Receptor Activity in Glioma Cells Impedes Tumor Inhibition of Fibroblast Growth Factor / Fibroblast Growth
We undertook a series of systematic studies to address the role of fibroblast growth factor/fibroblast growth factor receptor… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)